CUPERTINO, Calif., Oct. 24, 2014 /PRNewswire/ -- In conjunction with
DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial
results press release, you are invited to listen to the conference
call that will be broadcast live over the internet on Monday, November 3, 2014 at 4:30 pm Eastern Time (1:30
pm Pacific Time).
A live audio webcast of the presentation will be available by
accessing DURECT's homepage at http://www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a specialty pharmaceutical company developing
innovative drugs for pain and other chronic diseases, with
late-stage development programs including REMOXY®,
POSIDUR™, ELADUR®, and
TRANSDUR®-Sufentanil. DURECT's
proprietary oral, transdermal and injectable depot delivery
technologies may enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved
convenience, compliance, efficacy and safety for small molecule and
biologic drugs. For more information, please visit
www.durect.com.
NOTE: POSIDUR™, SABER®,
ORADUR®, and TRANSDUR® are trademarks of
DURECT Corporation. Other referenced trademarks belong to their
respective owners. REMOXY, POSIDUR, ELADUR and
TRANSDUR-Sufentanil are drug candidates under development and have
not been approved for commercialization by the U.S. Food and Drug
Administration or other health authorities.
Logo -
http://photos.prnewswire.com/prnh/20020717/DRRXLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-third-quarter-2014-earnings-conference-call-676096238.html
SOURCE DURECT Corporation